Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,716 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of PSA dynamics and oncological outcomes in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors.
Yamada Y, Sato K, Sakamoto S, Tsujino T, Saito S, Nishimura K, Fukushima T, Nakamura K, Yoshikawa Y, Matsunaga T, Maenosono R, Kanesaka M, Arai T, Sazuka T, Imamura Y, Komura K, Mikami K, Nakamura K, Fukasawa S, Chiba K, Naya Y, Nagata M, Komaru A, Nakatsu H, Azuma H, Ichikawa T. Yamada Y, et al. Among authors: matsunaga t. Int J Clin Oncol. 2024 Dec 10. doi: 10.1007/s10147-024-02676-z. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39656401
Pattern of Expression of MicroRNA in Patients with Radiation-Induced Bladder Injury.
Nakamura K, Ohno T, Inamoto T, Takai T, Uchimoto T, Fukushima T, Nishimura K, Yano Y, Nishio K, Kinoshita S, Matsunaga T, Nakamori K, Tsutsumi T, Tsujino T, Uehara H, Komura K, Takahara K, Azuma H. Nakamura K, et al. Among authors: matsunaga t. Oncology. 2024;102(7):1. doi: 10.1159/000535993. Epub 2023 Dec 29. Oncology. 2024. PMID: 38160665 Free PMC article.
Comparison of Radiographic Progression-Free Survival and PSA Response on Sequential Treatment Using Abiraterone and Enzalutamide for Newly Diagnosed Castration-Resistant Prostate Cancer: A Propensity Score Matched Analysis from Multicenter Cohort.
Komura K, Fujiwara Y, Uchimoto T, Saito K, Tanda N, Matsunaga T, Ichihashi A, Tsutsumi T, Tsujino T, Yoshikawa Y, Nishimoto Y, Takai T, Minami K, Taniguchi K, Tanaka T, Uehara H, Hirano H, Nomi H, Ibuki N, Takahara K, Inamoto T, Azuma H. Komura K, et al. Among authors: matsunaga t. J Clin Med. 2019 Aug 19;8(8):1251. doi: 10.3390/jcm8081251. J Clin Med. 2019. PMID: 31430900 Free PMC article.
Risk stratification for the prediction of overall survival could assist treatment decision-making at diagnosis of castration-resistant prostate cancer: a multicentre collaborative study in Japan.
Uchimoto T, Komura K, Fukuokaya W, Kimura T, Takahashi K, Fujiwara Y, Matsunaga T, Tsutsumi T, Tsujino T, Maenosono R, Yoshikawa Y, Taniguchi K, Tanaka T, Uehara H, Ibuki N, Hirano H, Nomi H, Takahara K, Inamoto T, Egawa S, Azuma H. Uchimoto T, et al. Among authors: matsunaga t. BJU Int. 2021 Feb;127(2):212-221. doi: 10.1111/bju.15187. Epub 2020 Aug 10. BJU Int. 2021. PMID: 32701219
Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer.
Uchimoto T, Komura K, Fukuokaya W, Kimura T, Takahashi K, Nishimura K, Nakamori K, Fujiwara Y, Matsunaga T, Tsutsumi T, Tsujino T, Maenosono R, Yoshikawa Y, Taniguchi K, Tanaka T, Uehara H, Ibuki N, Hirano H, Nomi H, Takahara K, Inamoto T, Egawa S, Azuma H. Uchimoto T, et al. Among authors: matsunaga t. Cancers (Basel). 2021 Jan 30;13(3):526. doi: 10.3390/cancers13030526. Cancers (Basel). 2021. PMID: 33573172 Free PMC article.
Risk Classification for Overall Survival by the Neutrophil-Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab-A Multicenter Collaborative Study in Japan.
Uchimoto T, Komura K, Fukuokaya W, Kimura T, Takahashi K, Yano Y, Nishimura K, Nakamori K, Fujiwara Y, Matsunaga T, Tsutsumi T, Tsujino T, Maenosono R, Yoshikawa Y, Taniguchi K, Tanaka T, Uehara H, Hirano H, Nomi H, Takahara K, Inamoto T, Egawa S, Azuma H. Uchimoto T, et al. Among authors: matsunaga t. Cancers (Basel). 2021 Jul 15;13(14):3554. doi: 10.3390/cancers13143554. Cancers (Basel). 2021. PMID: 34298768 Free PMC article.
Hemodialysis Initiation in Oldest-Old Patients: A Case Series.
Maenosono R, Matsunaga T, Yoshikawa Y, Nishimura K, Onaka H, Komura K, Uehara H, Azuma H. Maenosono R, et al. Among authors: matsunaga t. Case Rep Nephrol Dial. 2021 Sep 20;11(3):286-291. doi: 10.1159/000518706. eCollection 2021 Sep-Dec. Case Rep Nephrol Dial. 2021. PMID: 34722647 Free PMC article.
Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma.
Uchimoto T, Nakamura K, Komura K, Fukuokaya W, Yano Y, Nishimura K, Kinoshita S, Nishio K, Fukushima T, Nakamori K, Matsunaga T, Tsutsumi T, Tsujino T, Taniguchi K, Tanaka T, Uehara H, Takahara K, Inamoto T, Kimura T, Egawa S, Azuma H. Uchimoto T, et al. Among authors: matsunaga t. Urol Oncol. 2022 Jul;40(7):344.e11-344.e17. doi: 10.1016/j.urolonc.2022.02.012. Epub 2022 Mar 26. Urol Oncol. 2022. PMID: 35346572
Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma.
Inamoto T, Sato R, Matsushita Y, Uchimoto T, Nakamura KO, Komura K, Nishimura K, Yano Y, Nishio K, Kinoshita S, Fukushima T, Matsunaga T, Nakamori K, Tsutsumi T, Tsujino T, Uehara H, Takahara K, Miyake H, Azuma H. Inamoto T, et al. Among authors: matsunaga t. Cancer Diagn Progn. 2023 May 3;3(3):370-376. doi: 10.21873/cdp.10226. eCollection 2023 May-Jun. Cancer Diagn Progn. 2023. PMID: 37168961 Free PMC article.
Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer.
Nishimura K, Nishio K, Hirosuna K, Komura K, Hayashi T, Fukuokaya W, Ura A, Uchimoto T, Nakamura K, Fukushima T, Yano Y, Takahashi N, Nakamori K, Kinoshita S, Matsunaga T, Tsutsumi T, Tsujino T, Taniguchi K, Tanaka T, Uehara H, Takahara K, Inamoto T, Hirose Y, Kimura T, Egawa S, Azuma H. Nishimura K, et al. Among authors: matsunaga t. J Immunother Cancer. 2022 Jan;10(1):e003868. doi: 10.1136/jitc-2021-003868. J Immunother Cancer. 2022. PMID: 35039462 Free PMC article.
2,716 results